1404227-62-8

Basic information

• Product Name: 3-(4-chlorophenylsulfonamino)-5-(4-morpholinoquinazolin-6-yl)benzamide
• Synonyms: 3-(4-chlorophenylsulfonamino)-5-(4-morpholinoquinazolin-6-yl)benzamide
• CAS NO: 1404227-62-8
• Molecular Weight: 524
• Mol File: 1404227-62-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 3-(4-chlorophenylsulfonamino)-5-(4-morpholinoquinazolin-6-yl)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-chlorophenylsulfonamino)-5-(4-morpholinoquinazolin-6-yl)benzamide(1404227-62-8)
• EPA Substance Registry System: 3-(4-chlorophenylsulfonamino)-5-(4-morpholinoquinazolin-6-yl)benzamide(1404227-62-8)

Safety Data

• Hazardous Substances Data: 1404227-62-8(Hazardous Substances Data)

Upstream product

• 51339-40-3 3-bromo-5-nitrobenzoyl chloride 
• 6307-83-1 3-bromo-5-nitro-benzoic acid 
• 38267-96-8 6-bromo-4-chloroquinozoline 
• 32084-59-6 6-bromo-4-hydroxyquinazoline 
• 1261609-26-0 3-amino-5-bromobenzamide 
• 307538-52-9 4-(6-bromoquinazolin-4-yl)morpholine 
• 1404227-93-5 5-bromo-3-(4-chlorophenylsulfonamino)benzamide 
• 1404227-87-7 C₁₈H₂₄BN₃O₃ 
• 54321-80-1 3-bromo-5-nitrobenzamide 

Relevant articles and documents

Discovery of 2-methoxy-3-phenylsulfonamino-5-(quinazolin-6-yl or quinolin-6-yl)benzamides as novel PI3K inhibitors and anticancer agents by bioisostere

2-Substituted-3-sulfonamino-5-(quinazolin-6-yl or quinolin-6-yl)benzamides have been proposed as novel structures of PI3K inhibitors and anticancer agents based on bioisostere. In the present study, 2-substituted-3-sulfonamino-5-(4- morpholinoquinazolin-6-yl)benzamides and 2-methoxy-3-sulfonamino-5-(4- morpholinoquinolin-6-yl)benzamides were synthesized. Their antiproliferative activities in vitro were evaluated via MTT assay against four human cancer cell lines, including A549, HCT-116, U-87 MG and KB. The SAR of the title compounds was preliminarily discussed. Compound 1a with potent antiproliferative activity was tested for its inhibitory activity against PI3K and mTOR and its effect on the AKT and p-AKT473. The anticancer effect of 1a was evaluated in established nude mice U-87 MG xenograft model. The results suggest that compound 1a can significantly inhibit PI3K/AKT/mTOR pathway and tumor growth. These findings strongly support the assumption that title compounds are potent PI3K inhibitors and anticancer agents.